About Us Products Working at Napp Partnering Education Media Contact Press Releases The below press releases have been approved for communication with medical press and media. For general Napp news, please visit our News page. Napp Pharmaceuticals Announces European Commission Approval of Invokana® (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes July 2, 2020 FOR UK MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY The European Commission (EC) approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy criterion. Canagliflozin is the first therapy … READ MORE CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes May 29, 2020 Type 2 Diabetics miss out on a recommended annual kidney test which can signal irreversible damage that may lead to fatal complications, survey reveals February 20, 2020 Statement on the Public Health England Review on prescribed medicines that may cause dependence or withdrawal September 10, 2019 VIEW ALL PRESS RELEASES Stay connected LEGAL COOKIE POLICY PRIVACY NOTICE REGISTERED COMPANY MODERN SLAVERY STATEMENT TAX STRATEGY GROUP PENSION SCHEME PENSION IMPLEMENTATION STATEMENT STATEMENT OF INVESTMENT PRINCIPLES © 2021 NAPP PHARMACEUTICALS LIMITED. LAST UPDATED: MAY 2019